Child Safety Blog

An article recently published in the Journal of American Medical Association documents findings that associate atypical antipsychotics to weight gain in children who are first-time users of the drugs. The study, headed by Dr. Christoph Correll in New York, includes 272 youths age 4 to 19 and is “the largest and most definitive to date to establish a link between the drugs and weight gain,” writes Jonathan Rockoff of the Wall Street Journal.

The JAMA study examined four top-selling atypical antipsychotics (powerful drugs prescribed to treat schizophrenia and bipolar disorder): Abilify, Risperdal, Seroquel and Zyprexa. Among them, Zyprexa was found to cause the most weight gain: 19 pounds in 11 weeks. It was also found to “significantly raise levels of blood sugar, cholesterol, insulin and triglycerides,” thereby increasing users’ risk of diabetes and heart problems. Patients taking other three medications had an average of 10 to 13 pounds of weight gain.

Dr. Correll, the lead author of the study, recommends using extra caution in prescribing these atypical antipsychotics to youths under the age of 18, and encourages psychiatrists to frequently monitor the weight and metabolic rate of those who are taking these drugs.

Posted by Patrick A. Malone | Permalink | Email This Post

Posted In: Medication , Mental Health

Bookmark:

One in five American teenagers have an episode of depression before they turn 18. If untreated, adolescent-onset depression often returns during adulthood and becomes a chronic and persistent condition that is crippling and even life-threatening. One of the risk factors is having a depressed parent: that increases the odds of becoming depressed in one's teen years by two- to three-fold.

But an article appearing in the latest Journal of American Medical Association has good news, as reported by Shirley Wang of The Wall Street Journal: a multicenter trial conducted in 4 U.S. cities found that a group prevention program effectively reduced the risk of subsequent depression for a target group of teenagers.

The study involved 316 “at-risk” teenagers (ages 13-17). All had a history of clinical depression and parents who had had depressive disorders. The youths were assigned to either a group cognitive behavioral prevention program or usual mental health care. After 9 months of treatment, of the teenagers who were assigned to the group CB prevention program and whose parents were not depressed at the time of the study, only 11.7% had a new depressive episode. In contrast, among teenagers in usual care whose parents were not depressed at the time, 40% experienced another episode of depression.

Although the prevention program only worked for teenagers whose parents were not currently depressed, the new finding is still encouraging, shedding light on future research directions and clinical recommendations.

Posted by Patrick A. Malone | Permalink | Email This Post

Posted In: Mental Health

Bookmark:

Nearly two million American teenagers are afflicted with depression, and major medical groups are now recommending that pediatricians give a simple but detailed questionnaire to all their teenage patients to try to detect this condition so that treatment can be offered.

About 1 out of 20 teens suffer from depression, which has been linked to lower grades, more physical illness and drug use, as well as early pregnancy.

Questionnaires can accurately identify teens prone to depression, plus there's new evidence that therapy and/or some antidepressants can benefit them, according to a report from the U.S. Preventive Services Task Force, published in the April 2009 edition of the journal Pediatrics .

Accompanying the task force advisory in Pediatrics is a research review saying there have been few studies on the accuracy of depression screening tests, but the tests "have performed fairly well" among adolescents. Treatment can help with symptoms of depression, say the reviewers from Kaiser Permanente and the Oregon Evidence-Based Practice Center in Portland, Ore.

But careful monitoring is vital since there's "convincing evidence" that antidepressants can increase suicidal behavior in teens, according to the Preventive Services Task Force report.

The new recommendation reverses what the task force said in 2002, when it reported that there was not enough evidence to recommend for or against routine screening of adolescents for depression.

Posted by Patrick A. Malone | Permalink | Email This Post

Posted In: Mental Health

Bookmark:

Thirty-nine million prescriptions were written for American children in 2008 for drugs like Adderall and Concerta to treat attention deficit hyperactive disorder (ADHD), but new research suggests the drugs have only short-term benefit and may pose more harm to children than good if given for more than two years.

In a report in the Washington Post by Shankar Vendatam, scientists involved in a large federal study of the drugs sharply disagreed with one another about what the public should be told about their study results. One psychologist in the group of researchers said that parents needed to know that careful comparisons of the children in the study showed definite advantages of the drug treatment only in the first twenty-four months of use, and that longer use resulted in stunted growth, with drug-treated children typically an inch shorter and six pounds lighter than non-drug treated peers after 36 months of treatment. Another psychiatrist who participated in the study said long-term benefits were real but hard to demonstrate statistically.

The study is called the Multimodal Treatment Study of Children With ADHD (MTA). When its initial results were first published in 1999, a clear advantage was seen for behavior improvement in children who had taken the ADHD drugs in the first fourteen months of the study, compared to children who received only talk therapy or no treatment at all, and those results ignited a huge wave of popularity for the ADHD drugs with pediatricians and parents. But as the researchers have continued to follow the same children over the years, the advantage of drug therapy, at least as measurable statistically, disappeared.

Statistics, of course, do not necessarily apply in any one individual case. The take-away for parents is to be careful about any long-term use of drugs in their children and to continue to ask questions of doctors, and reach your own informed decisions about what to do.

Posted by Patrick A. Malone | Permalink | Email This Post

Posted In: Medication , Mental Health

Bookmark:

Nearly every week, we hear more evidence that American children are over-medicated, especially with drugs that affect mood and behavior. Most recently, a panel of experts has denounced the overuse of Risperdal, a powerful antipsychotic drug, for attention deficit disorder. The drug has too many side effects, including potential development of permanent muscle twitching, to justify its use in mild conditions like ADD for which other options exist, according to the expert panel convened by the Food & Drug Administration to advise it on labeling changes.

What is behind the explosion in use of antipsychotic drugs in children (besides Risperdal, they include Zyprexa, Seroquel, Abilify and Geodon) is a drumbeat of support from leaders in child psychiatry. But that leadership is tainted by their ties to the drug industry -- ties that frequently don't get mentioned in public when these same doctors are lecturing their colleagues and advising worried parents. One leader, Dr. Joseph Biederman, a child psychiatrist at Harvard, was revealed by a Congressional investigation to have accepted $1.4 million from manufacturers of antipsychotic drugs that he did not disclose to his university. Another psychiatrist leader, Dr. Charles B. Nemeroff of Emory, had to step down as chair of psychiatry after it was revealed that much of his consulting pay from drug makers, which totaled over $2.8 million in seven years, had been hidden from his university.

Now another influential psychiatrist has been exposed for his secret ties to the drug industry. He is Dr. Frederick Goodwin, former chief of the National Institute of Mental Health, who hosted a popular show on National Public Radio, "The Infinite Mind." Senator Charles Grassley of Iowa released data to the New York Times showing that Dr. Goodwin received $1.3 million from drug manufacturers from 2000 to 2007 for giving marketing lectures to other doctors. The money was never mentioned on his radio show, and NPR now says the show has been canceled and all reruns will stop soon.

According to the Times' Gardiner Harris, on one day in 2005, Dr. Goodwin received $2,500 from GlaxoSmithKline to give a talk about its mood stabilizer drug Lamictal at a Ritz Carlton resort in Florida. On his radio show broadcast the same day, Dr. Goodwin said that children with bipolar disorder who did not get treatment could suffer brain damage (a controversial prognosis) but he reassured his listeners that mood stabilizer drugs were a safe and effective way to treat the problem.

Senator Grassley has sponsored legislation to require drug makers to post publicly all the payments they make to doctor consultants. That would help the public to know whether the recommendations they see from doctors for medicating their children are truly unbiased or should be taken with a grain of salt.

Posted by Patrick A. Malone | Permalink | Email This Post

Posted In: Medication , Mental Health

Bookmark:

The largest study done yet of anxiety disorders in children and adolescents suggests that a combination of therapy and antidepressant medications is most effective tor treating disabling anxiety in these age groups.

The particular kind of therapy that was effective is called "cognitive behavior therapy" or "talk therapy." The difference between the combination of therapy and medication and each individual treatment alone was dramatic: 8 in 10 children who had the combination improved significantly, as opposed to 6 in 10 of those who had either the medication or the therapy alone.

The doctors who commented on the study in the article say this is something parents and insurance companies should both be very aware of.

Posted by Patrick A. Malone | Permalink | Email This Post

Posted In: Mental Health

Bookmark:

Infants who have a sibling with autism are at higher risk of becoming autistic themselves. At the University of Washington, researchers are testing whether or not a special intervention can be done to reduce the chances of autism in these high-risk babies.

Half of the mothers in the study will be taught to notice subtle cues from the babies and how to seize on these cues as opportunities to engage and communicate with them. These cues, it is hypothesized, indicate when the baby is "reaching out" to its parents.

If the study confirms the hypothesis, it means we will have a non-biochemical way of reducing the risk of autism.

Posted by Patrick A. Malone | Permalink | Email This Post

Posted In: Mental Health

Bookmark:

Sometimes children pose a greater risk to themselves than their surroundings do, as any mental health specialist could tell you. An alarming new study shows that the recent decline in the use of anti-depressants in children and teenagers has coincided with an increase in youth suicides.

Anti-depressant use among youths began to go down four years ago, when the Food and Drug Administration (FDA) issued an advisory regarding children and teens who were on anti-depressants and subsequently committed suicide. Later, in 2004, the FDA made a rule saying that anti-depressants had to be labeled for increased suicide risk in pediatric patients. In December 2006, the FDA expanded this rule so that it covered anti-depressant use in young adults as well.

Evidently there was cause for concern four years ago, but this new research suggests that these warnings are doing more harm than good. Prescriptions for these medications declined sharply after the FDA issued the warnings. But the youth suicide rates went up. Likewise, before 2003, an increase in anti-depressant prescription correlated with a decrease in youth suicide:

The researchers found that the reverse corollary was true. Increases in SSRI prescription rates coincided with decreases in suicide rates from 1998 to 2003. In the U.S., a 91 per cent increase in prescription rates coincided with a 33 per cent decrease in suicide rates.

The researchers therefore concluded that the FDA's analysis was flawed, pointing out that the FDA's study (suggesting a link between anti-depressant use and higher youth suicide rates) relied on a biased sample.

That said, there is always some ambiguity in this kind of research. That's why researchers must do multiple studies and why people need to get information from multiple sources. To find more information on mental health in children and teenagers, these links are a good place to start:

National Institute of Mental Health--Depression

National Institute of Mental Health--Children and Adolescents and Treatment of Children with Mental Disorders

Mental Health America--Disorders and Treatments

Posted by Patrick A. Malone | Permalink | Email This Post

Posted In: Mental Health

Bookmark: